BioSpace News Archive

Alimera Sciences today announced that Dan Myers, Chief Executive Officer, will be presenting at the annual HC Wainwright Global Investment Conference taking place September 5-6, 2018 at the St. Regis in New York, New York.

ImaginAb, Inc. and Centre for Probe Development and Commercialization (CPDC) today announced that they have entered into a development and manufacturing agreement for the supply of ImaginAb’s clinical-phase Positron Emission Tomography (PET) imaging agent Zr-89 IAB22M2C to key global geographies.

Dicerna Pharmaceuticals, Inc. today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in September.

The study was completed in March 2018 and demonstrated unequivocal superiority in gastrointestinal (“GI”) safety compared to naproxen, the most prescribed NSAID in the United States.

PolarityTE, Inc. (Nasdaq: COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced it will attend several upcoming healthcare conferences

Steward Health Care, the nation’s largest private, for profit physician led health care network, today named corporate communications veteran Jim Olson as Chief Communications Officer.

FairWarning®, leading provider of solutions that secure data in electronic health records and cloud-based applications, announced today their 100th Managed Privacy Services (MPS) customer.

Taking place in August, National ASC Month serves to promote awareness of the safe, affordable, exceptional care that ASCs provide.

Trovagene, Inc.today announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation (ODD) for Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of patients with Acute Myeloid Leukemia (AML).

Americans suffering from a “vacation deficit” are nearly two times as likely to show signs of moderately severe to severe depression compared to the national average, according to the 10th annual Allianz Global Assistance Vacation Confidence Index.